Frontiers in Pharmacology,
Год журнала:
2023,
Номер
14
Опубликована: Апрель 10, 2023
Background:
Glioma
patients
often
experience
unfavorable
outcomes
and
elevated
mortality
rates.
Our
study
established
a
prognostic
signature
utilizing
cuproptosis-associated
long
non-coding
RNAs
(CRLs)
identified
novel
biomarkers
therapeutic
targets
for
glioma.
Methods:
The
expression
profiles
related
data
of
glioma
were
obtained
from
Cancer
Genome
Atlas,
an
accessible
online
database.
We
then
constructed
using
CRLs
evaluated
the
prognosis
by
means
Kaplan-Meier
survival
curves
receiver
operating
characteristic
curves.
A
nomogram
based
on
clinical
features
was
employed
to
predict
individual
probability
patients.
Functional
enrichment
analysis
conducted
identify
crucial
CRL-related
enriched
biological
pathways.
role
LEF1-AS1
in
validated
two
cell
lines
(T98
U251).
Results:
developed
model
with
9
CRLs.
Patients
low-risk
had
considerably
longer
overall
(OS).
CRL
may
serve
independently
as
indicator
In
addition,
functional
revealed
significant
multiple
immunological
Notable
differences
observed
between
risk
groups
terms
immune
infiltration,
function,
checkpoints.
further
four
drugs
their
different
IC50
values
groups.
Subsequently,
we
discovered
molecular
subtypes
(cluster
one
cluster
two),
subtype
exhibiting
remarkably
OS
compared
subtype.
Finally,
that
inhibition
curbed
proliferation,
migration,
invasion
cells.
Conclusion:
signatures
confirmed
reliable
therapy
response
Inhibition
effectively
suppressed
growth,
gliomas;
therefore,
presents
itself
promising
biomarker
potential
target
Frontiers in Oncology,
Год журнала:
2024,
Номер
14
Опубликована: Авг. 9, 2024
Gliomas
are
primary
tumors
that
originate
in
the
central
nervous
system.
The
conventional
treatment
options
for
gliomas
typically
encompass
surgical
resection
and
temozolomide
(TMZ)
chemotherapy.
However,
despite
aggressive
interventions,
median
survival
glioma
patients
is
merely
about
14.6
months.
Consequently,
there
an
urgent
necessity
to
explore
innovative
therapeutic
strategies
treating
glioma.
foundational
study
of
regulated
cell
death
(RCD)
can
be
traced
back
Karl
Vogt's
seminal
observations
cellular
demise
toads,
which
were
documented
1842.
In
past
decade,
Nomenclature
Committee
on
Cell
Death
(NCCD)
has
systematically
classified
delineated
various
forms
mechanisms
death,
synthesizing
morphological,
biochemical,
functional
characteristics.
primarily
manifests
two
forms:
accidental
(ACD),
caused
by
external
factors
such
as
physical,
chemical,
or
mechanical
disruptions;
RCD,
a
gene-directed
intrinsic
process
coordinates
orderly
response
both
physiological
pathological
cues.
Advancements
our
understanding
RCD
have
shed
light
manipulation
modulation
-
either
through
induction
suppression
potentially
groundbreaking
approach
oncology,
holding
significant
promise.
obstacles
persist
at
interface
research
clinical
application,
with
impediments
encountered
translating
modalities.
It
increasingly
apparent
integrative
examination
molecular
underpinnings
imperative
advancing
field,
particularly
within
framework
inter-pathway
synergy.
this
review,
we
provide
overview
including
autophagy-dependent
anoikis,
ferroptosis,
cuproptosis,
pyroptosis
immunogenic
death.
We
summarize
latest
advancements
regulate
interconnections
between
different
processes.
By
comprehending
these
connections
developing
targeted
strategies,
potential
enhance
therapy
RCD.
As
a
primary
brain
cancer,
glioma
presents
significant
challenges
in
treatment
and
prognosis.
Identifying
reliable
biomarkers
is
crucial
for
improving
patient
outcomes.
This
study
focuses
on
the
ABCC3
gene,
exploring
its
function
as
standalone
predictive
indictor
correlation
with
immune
infiltration
resistance
to
chemotherapy
glioma.
A
multi-faceted
approach
was
adopted
this
analysis.
We
scrutinized
RNA
expression
patterns
of
gene
across
spectrum
cancer
types,
concentrated
focus
Our
methodological
arsenal
included
bioinformatics
analysis,
immunohistochemistry
(ICH),
western
blot
(WB),
cell
counting
Kit-8
(CCK8)
assays.
These
techniques
were
instrumental
gauging
prognostic
impact
elucidating
associations
resistance.
The
investigation
revealed
elevated
levels
high
grade
(HGG)
tissues
compared
lower
(LGG)
tissues.
Notably,
upregulation
associated
shorter
overall
survival
patients
Furthermore,
emerged
an
independent
factor
prognostication,
capability
1-,
3-,
5-year
rates.
far
response
concerned,
ABCC3's
correlates
positively
several
cells
checkpoint
genes.
also
uncovered
role
drug
resistance,
particularly
regarding
temozolomide
(TMZ),
therapeutic
agent
treatment.
reveals
biomarker
glioma,
survival,
enhanced
infiltration,
increased
chemotherapy.
findings
emphasize
promise
novel
target
therapies.
Background
Multiple
myeloma
(MM)
is
a
hematological
malignancy
with
the
proliferation
of
malignant
plasma
cells.
Numerous
studies
have
highlighted
critical
role
ferroptosis
in
MM.
However,
how
to
use
ferroptosis-related
genes
(FRGs)
for
prognostic
prediction
and
treatment
guidance
MM
remains
unknown.
Frontiers in Oncology,
Год журнала:
2021,
Номер
11
Опубликована: Дек. 1, 2021
Glioblastoma
represents
the
most
devastating
form
of
human
brain
cancer,
associated
with
a
very
poor
survival
rate
patients.
Unfortunately,
treatment
options
are
currently
limited
and
gold
standard
pharmacological
chemotherapeutic
drug
temozolomide
only
slightly
increases
rate.
Experimental
studies
have
shown
that
efficiency
can
be
improved
by
inducing
ferroptosis
–
recently
discovered
cell
death,
which
is
different
from
apoptosis,
necrosis,
or
necroptosis
and,
characterized
lipid
peroxidation
reactive
oxygen
species
accumulation.
Ferroptosis
also
activated
to
improve
malignant
stages
neuroblastoma,
meningioma,
glioma.
Due
their
role
in
cancer
treatment,
ferroptosis-gene
signatures
been
evaluated
for
ability
predict
Despite
positive
effects
during
chemotherapy,
drugs
used
induce
such
as
erastin
sorafenib
well
genetic
manipulation
key
players
cystine-glutamate
exchanger
xCT
glutathione
peroxidase
GPx4
impact
neuronal
function
cognitive
capabilities.
In
this
review,
we
give
an
update
on
tumors
summarize
healthy
tissues.
Frontiers in Pharmacology,
Год журнала:
2023,
Номер
14
Опубликована: Апрель 10, 2023
Background:
Glioma
patients
often
experience
unfavorable
outcomes
and
elevated
mortality
rates.
Our
study
established
a
prognostic
signature
utilizing
cuproptosis-associated
long
non-coding
RNAs
(CRLs)
identified
novel
biomarkers
therapeutic
targets
for
glioma.
Methods:
The
expression
profiles
related
data
of
glioma
were
obtained
from
Cancer
Genome
Atlas,
an
accessible
online
database.
We
then
constructed
using
CRLs
evaluated
the
prognosis
by
means
Kaplan-Meier
survival
curves
receiver
operating
characteristic
curves.
A
nomogram
based
on
clinical
features
was
employed
to
predict
individual
probability
patients.
Functional
enrichment
analysis
conducted
identify
crucial
CRL-related
enriched
biological
pathways.
role
LEF1-AS1
in
validated
two
cell
lines
(T98
U251).
Results:
developed
model
with
9
CRLs.
Patients
low-risk
had
considerably
longer
overall
(OS).
CRL
may
serve
independently
as
indicator
In
addition,
functional
revealed
significant
multiple
immunological
Notable
differences
observed
between
risk
groups
terms
immune
infiltration,
function,
checkpoints.
further
four
drugs
their
different
IC50
values
groups.
Subsequently,
we
discovered
molecular
subtypes
(cluster
one
cluster
two),
subtype
exhibiting
remarkably
OS
compared
subtype.
Finally,
that
inhibition
curbed
proliferation,
migration,
invasion
cells.
Conclusion:
signatures
confirmed
reliable
therapy
response
Inhibition
effectively
suppressed
growth,
gliomas;
therefore,
presents
itself
promising
biomarker
potential
target
